AIMS: To determine the systemic thrombogenic effect of radiofrequency catheter isolation of the pulmonary veins (PVI) in the treatment of atrial fibrillation. METHODS AND RESULTS: We studied endothelial damage marker (von Willebrand factor [vWf]), fibrinolysis markers (tissue plasminogen activator [t-PA], plasminogen activator inhibitor-1 [PAI-1]) and coagulation activation markers (D-dimer [DD]) in 30 patients (pts) undergoing PVI. Heparin was administered continuously after double transseptal puncture in all pts. Concentrations of vWf and t-PA were significantly increased after accomplishing PVI compared to the baseline values, and elevated levels persisted 24 hours later ( p < 0.01). PAI-1 levels decreased following PVI compared to the baseline levels ( p = 0.02). PAI-1 levels normalized 24 hours after the procedure. DD increased continuously during the procedure with the peak following PVI ( p < 0.01). Higher DD concentrations persisted 24 hours later ( p = 0.02). In a multivariate analysis, total procedure time correlated significantly with the peak vWf and DD concentrations, while total RF energy dose correlated only with peak vWf ( r = 0.82). Time to heparin administration correlated with DD levels prior to the first RF pulse ( r = 0.83, p < 0.01) as well as after PVI ( r = 0.75, p < 0.01). A group of patients heparinized within the first hour of the PVI procedure had normal preablation DD levels and significantly mitigated DD levels following PVI compared to the group of patients heparinized later ( p < 0.01). CONCLUSIONS: Pulmonary vein ablations cause an increased systemic procoagulant state as reflected by fibrin turnover, fibrinolysis activation and endothelial perturbation. The activation of the coagulation cascade could be decreased by early heparin administration.
AIMS: To determine the systemic thrombogenic effect of radiofrequency catheter isolation of the pulmonary veins (PVI) in the treatment of atrial fibrillation. METHODS AND RESULTS: We studied endothelial damage marker (von Willebrand factor [vWf]), fibrinolysis markers (tissue plasminogen activator [t-PA], plasminogen activator inhibitor-1 [PAI-1]) and coagulation activation markers (D-dimer [DD]) in 30 patients (pts) undergoing PVI. Heparin was administered continuously after double transseptal puncture in all pts. Concentrations of vWf and t-PA were significantly increased after accomplishing PVI compared to the baseline values, and elevated levels persisted 24 hours later ( p < 0.01). PAI-1 levels decreased following PVI compared to the baseline levels ( p = 0.02). PAI-1 levels normalized 24 hours after the procedure. DD increased continuously during the procedure with the peak following PVI ( p < 0.01). Higher DD concentrations persisted 24 hours later ( p = 0.02). In a multivariate analysis, total procedure time correlated significantly with the peak vWf and DD concentrations, while total RF energy dose correlated only with peak vWf ( r = 0.82). Time to heparin administration correlated with DD levels prior to the first RF pulse ( r = 0.83, p < 0.01) as well as after PVI ( r = 0.75, p < 0.01). A group of patients heparinized within the first hour of the PVI procedure had normal preablation DD levels and significantly mitigated DD levels following PVI compared to the group of patients heparinized later ( p < 0.01). CONCLUSIONS: Pulmonary vein ablations cause an increased systemic procoagulant state as reflected by fibrin turnover, fibrinolysis activation and endothelial perturbation. The activation of the coagulation cascade could be decreased by early heparin administration.
Authors: A S Manolis; V Vassilikos; T N Maounis; L Psarros; H Melita-Manolis; D Papatheou; A Haliassos; V Christopoulou-Cokkinou; D V Cokkinos Journal: Am J Cardiol Date: 1997-02-15 Impact factor: 2.778
Authors: A S Manolis; H Melita-Manolis; V Vassilikos; T Maounis; J Chiladakis; V Christopoulou-Cokkinou; D V Cokkinos Journal: J Am Coll Cardiol Date: 1996-11-01 Impact factor: 24.094
Authors: A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans Journal: Circulation Date: 1998-11-24 Impact factor: 29.690
Authors: M R Epstein; L D Knapp; M Martindill; J A Lulu; J K Triedman; H Calkins; S K Huang; E P Walsh; J P Saul Journal: Am J Cardiol Date: 1996-03-15 Impact factor: 2.778
Authors: Charles J Bruce; Paul A Friedman; Om Narayan; Thomas M Munger; Stephen C Hammill; Douglas L Packer; Samuel J Asirvatham Journal: J Interv Card Electrophysiol Date: 2008-06-21 Impact factor: 1.900
Authors: Pasquale Santangeli; Luigi Di Biase; Javier E Sanchez; Rodney Horton; Andrea Natale Journal: Cardiol Res Pract Date: 2011-04-26 Impact factor: 1.866
Authors: Jelena Kornej; Borislav Dinov; Andrew D Blann; Sascha Rolf; Arash Arya; Josephine Schmidl; Daniela Husser; Gerhard Hindricks; Andreas Bollmann; Gregory Y H Lip Journal: PLoS One Date: 2014-11-12 Impact factor: 3.240
Authors: Orsolya Hajas; Zsuzsa Bagoly; Noémi K Tóth; Réka Urbancsek; Alexandra Kiss; Kitti B Kovács; Ferenc Sarkady; Attila Nagy; Anna V Oláh; László Nagy; Marcell Clemens; László Csiba; Zoltán Csanádi Journal: Cardiol Res Pract Date: 2020-02-12 Impact factor: 1.866